Pharmaceutical composition
AssigneeKyowa Kirin Co., Ltd.
InventorsHiroki Haniuda, Sachiko Enokizono, Tomoyuki Nakazato, Takuya Tokuda, Norie Fujiki
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.
Claims19
A method for treating an ophthalmic disease, comprising administering a therapeutic agent comprising a vascular endothelial growth factor (VEGF) receptor inhibitor in a nanoparticle form, wherein the VEGF receptor inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt, and the therapeutic agent is eye drops.
A method for producing a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor in a nanoparticle form, the VEGF receptor inhibitor is a compound represented by formula (II):
- or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate of the compound or the salt, and the therapeutic agent for the ophthalmic disease is eye drops,
- wherein the method comprises the step of milling a vascular endothelial growth factor (VEGF) receptor inhibitor into a nanoparticle form.
Dependencies are inferred from the claim text.